TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04406350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative tight control of respiratory end-tidal gases
Description: Control of ET CO2 and ET O2 during conduct of anesthesia.
Study: NCT03892629

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Baduanjin exercise
Description: Participants received Baduanjin exercise. Each Baduanjin exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise
Description: Participants received Baduanjin exercise. Each Baduanjin exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Instrument rehabilitation
Description: Participants received pulmanory rehabilitation by using tri-ball respiratory trainer. Each instrument exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Instrument rehabilitation
Description: Participants received pulmanory rehabilitation by using tri-ball respiratory trainer. Each instrument exercise session lasts 30 minutes and continues twice a day, 5 times per week for 12 weeks
Study: NCT05582980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS
Description: See detail in arm/group descriptions regarding the intervention.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HD-tDCS
Description: See detail in arm/group descriptions regarding the intervention.
Study: NCT04646135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg/ml
Description: Lorazepam will be administered intravenously according to the scheduled sequences.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg/ml
Description: Lorazepam will be administered intravenously according to the scheduled sequences.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg/ml
Description: Lorazepam will be administered intravenously according to the scheduled sequences.
Study: NCT00524810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Description: Caelyx 30 mg/m² day 1 every 3 weeks
Study: NCT02221856

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motion View
Description: Motion View, a software we are using to place brackets virtually on a 3D rendition of a patients teeth, will be used to indirectly bond brackets onto patient's teeth with a 3D printed plastic transfer JIG in which the brackets will be precisely placed on the patients teeth according to the computer-guided software.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Orthodontic Treatment
Description: orthodontic treatment using non-customized brackets and stock wires
Study: NCT04278378

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin
Description: 1.6 mg riboflavin / day for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Riboflavin
Description: 1.6 mg riboflavin / day for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: 0.4 mg folic acid / day for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: 0.4 mg folic acid / day for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02904902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Subcutaneous Injection
Study: NCT01375205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil Restoraderm
Description: Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subjects will apply Johnson\&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson\&Johnson cleanser.
Study: NCT04441723

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteosynthesis with Gamma 3 nail , using a dynamic lag screw as a proximal fixation.
Description: Closed reduction and surgical stabilization of intertrochanteric hip fractures using Gamma 3 nail , with dynamic lag screw as proximal fixation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Osteosynthesis with Gamma 3 nail , using a static lag screw as a proximal fixation.
Description: Closed reduction and surgical stabilization of intertrochanteric hip fractures using Gamma 3 nail , with static lag screw as proximal fixation
Study: NCT04453514

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-informed yoga video recording
Description: Pre-recorded video of a 45-minute trauma-informed yoga practice. The yoga practice can be done standing or sitting in a chair. The yoga practice is comprised of slow, gentle movements combined with paying attention to the body and the breath. The practice uses invitational language and encourages participants to make choices and customize the movements according to their individual needs.
Study: NCT03885011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSF-1
Description: This treatment arm consists of 2 different concentrations of CSF-1. Subjects randomized to the CSF-1 treatment arm will receive their first dose of CSF-1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 arm will now receive a different concentration of CSF-1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSF-1 Component #1
Description: This treatment arm consists of 2 different concentrations of CSF-1 Component #1.~Subjects randomized to the CSF-1 Component #1 treatment arm will receive their first dose of CSF-1 Component #1 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #1 arm will now receive a different concentration of CSF-1 Component #1. Subjects will continue dosing twice a day in both eyes for approximately 1 week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CSF-1 Component #2
Description: This treatment arm consists of a single concentration of CSF-1 Component #2. Subjects randomized to the CSF-1 Component #2 treatment arm will receive their first dose of CSF-1 Component #2 in-office at Visit 2. All subjects will dose twice a day in both eyes with a single drop for approximately 1 week. At Visit 3, subjects randomized to the CSF-1 Component #2 arm will continue dosing with the same concentration of CSF-1 Component #2. Subjects will continue dosing twice a day in both eyes for approximately 1 week.
Study: NCT01750736

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augmented Exercise and Manual Therapy
Description: Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform the augmented exercise at home and at each data collection session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General Exercise and Manual Therapy
Description: Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform general range of motion exercises for the neck at home and at each data collection session.
Study: NCT00896428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methoxyverapamil (gallopamil)
Description: 200 mg/day (1 tablet 100 mg morning and evening) for 12 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo.
Description: 1 tablet morning and evening for 12 months
Study: NCT04309929

Intervention type: DRUG
Intervention: Analgesics
Description: All patients will undergo the anesthesiological and surgical treatment provided for the patient's clinical conditions and in no case will the patients undergo a change in the normal diagnostic-therapeutic path due to participation in this study.
Study: NCT01674621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide Transdermal (50 mcg)
Description: Abaloparatide Transdermal Microneedle Active Patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide Transdermal (100 mcg)
Description: Abaloparatide Transdermal Microneedle Active Patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide Transdermal (150 mcg)
Description: Abaloparatide Transdermal Microneedle Active Patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abaloparatide Injection (80 mcg)
Description: Abaloparatide Subcutaneous Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abaloparatide Placebo
Description: Abaloparatide Transdermal Microneedle Placebo Patch
Study: NCT03280082

Intervention type: OTHER
Group type: OTHER
Intervention: MUAC Program
Description: All children admitted to the PB program will receive standard care according to the national Protocol and that of MSF, including preventive and therapeutic care at admission as well as hospital care in case of clinical complications. There will be no change in the Protocol for the hospital care to the CRENI (Center of Intensive Nutritional Rehabilitation). RUTF (Ready-to-Use therapeutic food) will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Program
Description: All children admitted to the standard program will receive standard care according to national and MSF protocols, including preventive and therapeutic care on admission as well as hospital care in case of clinical complications. RUTF will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
Study: NCT01194128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Support
Description: The intervention is comprised of three modules, each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information only control group
Description: Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition. Also provided will be a resource guide containing local contact information.
Study: NCT02846116

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic crown

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic crown
Study: NCT03494062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home-based exercise training
Study: NCT01312987

Intervention type: DIETARY_SUPPLEMENT
Group type: NO_INTERVENTION
Intervention: Lipid-based nutritional supplement
Description: After gradual introduction of the lipid-based nutritional supplement, daily dose per child is as follows:~3 teaspoons 3 x day for children younger than 12 months 4.5 teaspoons 3 x day for children older than 12 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid-based nutritional supplement
Description: After gradual introduction of the lipid-based nutritional supplement, daily dose per child is as follows:~3 teaspoons 3 x day for children younger than 12 months 4.5 teaspoons 3 x day for children older than 12 months
Study: NCT02151734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KALOMIN™ Tab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Umckamin syrup
Study: NCT02420145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 12 weeks of yoga, twice weekly for 90 minutes plus a whole-day workshop
Study: NCT01725386

Intervention type: DRUG
Intervention: Capecitabine
Description: Oral tablet(s) administered according to prescribing information

Intervention type: DRUG
Intervention: Capecitabine
Description: Oral tablet(s) administered according to prescribing information
Study: NCT00524810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Taxotere 75 mg/m² day 2 every 3 weeks
Study: NCT02502487

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dorsal Penile Nerve Block
Description: Dorsal penile nerve block with 0.33% ropivacaine using 22-G needle in the sub-pubic space at the base of the penis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dorsal Penile Nerve Block
Description: Dorsal penile nerve block with 0.33% ropivacaine using 22-G needle in the sub-pubic space at the base of the penis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.33% Ropivacaine administered around dorsal penile nerve using 22-G needle in the sub-pubic space at the base of the penis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.33% Ropivacaine administered around dorsal penile nerve using 22-G needle in the sub-pubic space at the base of the penis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine
Description: 1% Tetracaine gel instilled into urethra

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tetracaine
Description: 1% Tetracaine gel instilled into urethra
Study: NCT06279780

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: very low-calorie diet
Description: Subjects undergo two cycles of a very-low-calorie diet (VLCD) for 6 weeks each, alternating with a hypocaloric diet (12 weeks). The dietetic intervention consists of a VLCD using a liquid formula (Optisource Plus, Nestlé S.A., Vevey, Switzerland), providing 52.8 g protein, 75.0 g carbohydrates, 13.5 g fat, 11.4 g fiber, and essential vitamins and minerals based on Recommended Dietary Allowances (RDA). This formula supplies 2738 kJ/day (654 kcal/day), replacing the participants' three daily meals. Following this and before the second VLCD cycle, a dietician performs an individualized nutritional assessment to calculate the resting energy expenditure, and personalized hypocaloric diets were prepared, reducing 500 kcal for each individual on their daily caloric expenditure, maintaining the recommended intake of each of the macronutrients (55% carbohydrates, 30% fats and 15% proteins) for 12-weeks.
Study: NCT02174159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulonivirine
Description: MK-8507 administered as a single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulonivirine
Description: MK-8507 administered as a single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulonivirine
Description: MK-8507 administered as a single oral dose
Study: NCT01705314

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D supplements
Description: Participants will receive 7mls of D-drops (14,000U/week of vitamin D)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 7mls of placebo drops per week for 8 months.
Study: NCT01582412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: oral
Study: NCT03992989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Bolero M90-M
Description: The Phonak Bolero M90-M is a Behind-the-Ear Hearing aid with direct connectivity functionality from Phonak which will be fitted to the participants individual Hearing loss

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Roger Select
Description: The Roger Select is an accessory which can be connected to a compatible hearing aid. It offers an external microphone which streams signals directly to the connected hearing aid.
Study: NCT00965341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
Study: NCT03196466

Intervention type: BIOLOGICAL
Intervention: Valproic acid
Description: titration

Intervention type: BIOLOGICAL
Intervention: Valproic acid
Description: titration

Intervention type: BIOLOGICAL
Intervention: carbamazepine
Description: titration
Study: NCT04191681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril-Valsartan
Description: Sacubitril-valsartan at low or equivalent dose to be initiated or added to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
Study: NCT03887871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harnal-D Tab.
Description: Harnal-D Tab. 1T single oral administration after meal
Study: NCT04191681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (standard-of-care) arm
Description: Other oral vasodilator therapy to be continued or initiated to patients randomized to this arm, and titrated up every 2-4 weeks, per standard practice guidelines and label recommendations per physician's discretion.
Study: NCT03887871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Harnal-D Tab.
Description: Harnal-D Tab. 1T single oral administration after meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chong Kun Dang Tamsulosin HCl Tab.
Description: Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration after meal
Study: NCT03196466

Intervention type: BIOLOGICAL
Intervention: carbamazepine
Description: titration
Study: NCT03887871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chong Kun Dang Tamsulosin HCl Tab.
Description: Chong Kun Dang Tamsulosin HCl Tab. 1T single oral administration after meal
Study: NCT04509583

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PROFortil
Description: Multi-micronutrient supplement (PROfortil™, twice daily) plus Vitamin E (Enat 400, once per day) in 3 months

Intervention type: OTHER
Group type: OTHER
Intervention: Vitamin E
Description: Only Vitamin E (Enat 400, once per day) in 3 months
Study: NCT03106337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shear-Wave Elastography
Description: Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
Study: NCT04056117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella 4V
Description: Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella 4V
Description: Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella 4V
Description: Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella 4V
Description: Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella 4V
Description: Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.
Study: NCT01596218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Starting dose is 0.6 mg/kg weekly x 3
Study: NCT01261715

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond- liquid skin adhesive
Description: Dermabond- liquid skin adhesive
Study: NCT00002537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Study: NCT03196466

Intervention type: BIOLOGICAL
Intervention: phenobarbital
Description: titration
Study: NCT04056117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella 4V
Description: Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella 4V
Description: Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella 4V
Description: Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.
Study: NCT00002537

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04056117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella 4V
Description: Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella 4V
Description: Non-adjuvanted and adjuvanted Shigella 4V administrated at 4 different doses: very low, low, medium and high.
Study: NCT01603563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped Care TF-CBT
Description: Stepped Care TF-CBT patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard TF-CBT
Description: Standard TF-CBT patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, \& trauma narrative etc.).